Prognostic value of systemic inflammation response index (SIRI) in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors: A meta-analysis

被引：0
|
作者：
Gu, X. [1 ]
机构：
[1] Zhengzhou Univ, Dept Radiat Oncol, Affiliated Hosp 1, Zhengzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.521
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1585 / S1586
页数：2
相关论文
共 50 条
  • [1] Prognostic value of systemic inflammation response index in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors: a meta-analysis
    Gu, Xiaobin
    Han, Xiaodan
    Shen, Yanli
    Shi, Yonggang
    ANNALS OF MEDICINE, 2024, 56 (01)
  • [2] The Prognostic Value of Gastric Immune Prognostic Index in Gastric Cancer Patients Treated With PD-1/PD-L1 Inhibitors
    Chen, Li
    Zhao, Ruihu
    Sun, Hao
    Huang, Rong
    Pan, Hongming
    Zuo, Yanjiao
    Zhang, Lele
    Xue, Yingwei
    Li, Xingrui
    Song, Hongjiang
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [3] Efficacy of PD-1/PD-L1 Immune Checkpoint Inhibitors for Advanced NSCLC According to PD-L1 Expression: A Meta-Analysis
    Ma, K.
    Guo, Y.
    Wang, Y.
    Wang, X.
    Xu, Y.
    Sun, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S584 - S584
  • [4] Evaluation of PD-L1 biomarker for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatments for urothelial carcinoma patients: A meta-analysis
    Rui, Xin
    Gu, Ting-Ting
    Pan, Hua-Feng
    Zhang, Hui-Zhi
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 67 : 378 - 385
  • [5] A meta-analysis of the efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors as treatments for metastatic bladder cancer
    Fan, Zhongyuan
    Liang, Ye
    Yang, Xuecheng
    Li, Bin
    Cui, Lili
    Luo, Lei
    Jia, Yuefeng
    Wang, Yonghua
    Niu, Haitao
    ONCOTARGETS AND THERAPY, 2019, 12 : 1791 - 1801
  • [6] Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
    Iosune Baraibar
    Ignacio Melero
    Mariano Ponz-Sarvise
    Eduardo Castanon
    Drug Safety, 2019, 42 : 281 - 294
  • [7] Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
    Baraibar, Iosune
    Melero, Ignacio
    Ponz-Sarvise, Mariano
    Castanon, Eduardo
    DRUG SAFETY, 2019, 42 (02) : 281 - 294
  • [8] Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
    Shen, Xian
    Zhao, Bin
    BMJ-BRITISH MEDICAL JOURNAL, 2018, 362
  • [9] Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in colorectal cancer: a meta-analysis
    Jin, Chunhui
    Zhu, Xiaodan
    Huang, Xiaona
    Gong, Tingjie
    Wei, Zhipeng
    You, Jianliang
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 11 (03) : 203 - 212
  • [10] The predictive value of PD-L1 expression in patients with advanced hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors: A systematic review and meta-analysis
    Yang, Yao
    Chen, Dongbo
    Zhao, Bigeng
    Ren, Liying
    Huang, Rui
    Feng, Bo
    Chen, Hongsong
    CANCER MEDICINE, 2023, 12 (08): : 9282 - 9292
12345